A combination of IK-930 with MEKi and EGFRi resulted in antitumor activity in vivo in KRAS- and EGFR-mutant xenograft models of colorectal carcinoma cells and NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.